Infectious Disease Market Size 2024-2028

The infectious disease market size is forecast to increase by USD 130.3 billion at a CAGR of 13.64% between 2023 and 2028. The increasing prevalence of infectious diseases is the key factor driving the market growth. There has been an increase in the prevalence of infectious diseases, driving the demand for infectious disease diagnostics. Globally, infectious disease outbreaks have increased due to changing lifestyles, which result in reduced immunity. The pattern of the incidence of infectious disease has also been changing with the evolution of drug-resistant pathogens. HIV/AIDS is a leading cause of death in many countries.

 What will the Size of the Market be During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

By Product 

The market size growth by the drugs segment will be significant during the forecast period. As per the WHO 2019 Global Tuberculosis Report, the total number of TB-infected patients across the world was estimated to be 6.3 million. The figure fell to 4.9 million in 2020. Fewer cases of TB were notified in 2020 owing to the outbreak of the COVID-19 pandemic, which, in turn, led to over half a million deaths from the disease globally in 2020. Thus, the rising number of cases of infectious diseases is expected to increase the demand for TB drugs, thereby driving the growth of the market during the forecast period.

Get a glance at the market contribution of various segments Request a PDF Sample

The drugs segment showed a gradual increase in market share with USD 44.50 billion in 2018. The drugs used for the treatment of infectious diseases act either by inhibiting the spread of an infectious agent or by destroying the infectious agent. Bacteria such as Staphylococcus, Streptococcus, Pseudomonas, E. coli, Clostridium difficile, and Listeria are the most common causes of infections leading to skin infections, tonsillitis, cancer, diarrhea, abdominal pain, and fever. Infections caused by viruses are the common cold, flu, chickenpox, COVID-19, and Ebola. Fungal infections such as thrush affect the oral cavities, while protozoal infections can cause intestinal infections. Hence, anti-infective drugs are required to destroy infectious agents that cause various diseases in human beings, including tuberculosis (TB), sepsis, and smallpox. 

By Region

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 45% of market growth by 2028. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is led by the US because of the presence of top players such as Gilead Sciences, Inc., Johnson & Johnson, Pfizer, and AbbVie, which generate high revenue from their leading drugs, including generic drugs. In addition, these companies invest in marketing and patient awareness initiatives. The US is one of the major contributors to the market in the region. This is because of the presence of top players, including Aridis Pharmaceuticals, Entasis Therapeutics, and Merck. The market is expected to have accelerated growth momentum during the forecast period. The major factors driving the market growth include the development and launch of drugs for the treatment of infectious diseases and the proper treatment of the patient population. 

Market Dynamics and Customer Landscape

Point-of-care diagnostic testing plays a pivotal role in combating infectious diseases, offering rapid results and enabling prompt diagnosis in settings like urgent care centers, emergency rooms, and ambulances. It significantly impacts patient outcomes by facilitating early detection and treatment while enhancing infection control and personal health practices. However, challenges persist due to inadequate infrastructure, particularly in regions with poor water sanitation. Advanced technologies such as Immunodiagnostics, Polymerase Chain Reaction (PCR), and Next-Generation Sequencing (NGS) empower clinical microbiology by enabling precise identification of pathogens like Hepatitis, Chlamydia Trachomatis Genital Infection, and syphilis. Additionally, vigilance against mosquito-borne diseases remains critical, prompting continuous advancements in laboratory testing and PoC testing for conditions like Gonorrhea and RNA viruses.

Key Market Driver

The increasing prevalence of infectious diseases is the key factor driving market growth. There has been an increase in the prevalence of infectious diseases. Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites. Globally, infectious disease outbreaks have increased due to changing lifestyles, which result in reduced immunity. The pattern of infectious disease incidence has also been changing with the evolution of drug-resistant pathogens. HIV/AIDS is a leading cause of death in many countries.

Additionally, as per the UNAIDS data for 2020, 680,000 people died from AIDS-related illnesses across the world. The incidence of certain infectious diseases has also decreased in many countries. For instance, the prevalence of meningococcal disease, which is caused by the bacterium Neisseria meningitidis, has declined in the US. According to the CDC, in 2019, only 370 new cases of meningococcal disease were reported in the US. Globally, the incidence and prevalence of infectious diseases have increased due to climate change and its consequences. This is expected to be a major driver for market growth during the forecast period.

Significant Market Trend

The development of novel drugs will fuel market growth. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. For instance, researchers at the Indian Institute of Science have discovered a new drug combination that promises better outcomes in treating tuberculosis. In patients with tuberculosis, the bacterium continues to develop resistance against certain old drugs.

Furthermore, according to researchers, the new drug called pranlukast can kill the tuberculosis bacterium as well as weaken its survival strategies within cells. This discovery will provide an opportunity to use this novel drug combination in tuberculosis therapeutics. Furthermore, researchers are searching for new tuberculosis drugs to complement bedaquiline and expand the treatment options available to healthcare professionals worldwide. Such developments are expected to have a positive impact on the growth of the market during the forecast period.

Major Market Challenge

The adverse effects of anti-infective drugs are a major challenge to the market growth. Multiple drugs are being approved by the US FDA and are being indicated for the treatment of different infectious diseases. However, these drugs are associated with adverse effects. The potential adverse effects of anti-infective drugs are bone marrow growth suppression, anaphylaxis, nephrotoxicity, and ototoxicity. 

Similarly, Saquinavir is an antiviral medicine that prevents the human immunodeficiency virus (HIV) from multiplying in the patient's body. The drug has some life-threatening side effects if it is taken along with cholesterol medication (such as Mevacor, Altoprev, and Advicor) and heart rhythm medications (including amiodarone, disopyramide, and dofetilide). The adverse effects of anti-infective drugs can reduce patient compliance, thereby leading to a decline in the growth of the market.

Customer Landscape

The market forecasting report includes the adoption lifecycle of the infectious disease therapeutics market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates?in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Who are the Major Market Companies?                            

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the infectious disease therapeutics market.

Bio-rad Laboratories Inc.- The company offers therapeutics for infectious diseases that help in earlier diagnosis, appropriate therapy selection, personalized care, and infectious disease monitoring.

We also have detailed analyses of the market’s competitive landscape and offer information on 15 market companies, including :

• Danaher Corp.
• F. Hoffmann La Roche Ltd.
• Genetic Signatures Ltd.
• Grifols SA
• Hologic Inc.
• Meridian Bioscience Inc.
• Meril Life Sciences Pvt. Ltd.
• OraSure Technologies Inc.
• PerkinElmer Inc.
• QIAGEN NV
• Siemens AG
• Sysmex Corp.
• Trinity Biotech Plc
• Abbott Laboratories

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak. 

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Region Outlook
  • ROW
    • Australia
    • Argentina
    • Rest of the world

• • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Australia

Market Analyst Overview

The market encompasses a broad spectrum of conditions, driving demand for urgent care centres, diagnostic kits, and consumables for various tests, including RT-PCR, influenza, and SARS-CoV-2. With applications in respiratory diseases and infections, the market caters to hospitalizations and non-notifiable infections, addressing challenges like hospital-acquired infections and communicable diseases. Diagnostic methods range from chest X-rays to PCR testing, targeting respiratory secretions and blood samples. Advanced technologies like isothermal nucleic acid amplification facilitate rapid and accurate detection of pathogens such as gonorrhea and Hepatitis C. From clinical laboratories to physician offices, the market serves diverse healthcare settings, emphasizing preventative healthcare and personalized medicine supported by genomics and proteomics research.

Further, the market is a vital component of healthcare, addressing conditions through a plethora of diagnostic tests such as CT scans, physical exams, and laboratory tests. It caters to a range of infections, including respiratory infections and sexually transmitted infections like gonorrhea and HIV hepatitis. Advanced Amplification Technology and Kits and Reagents enable precise detection of pathogens like Human Papillomavirus (HPV) and Neisseria gonorrhea. Healthcare facilities, including hospitals and reference laboratories, play a crucial role, with support from centralised laboratories and point-of-care testing. Government-funded programmes and initiatives target areas like hospital-acquired infections and geriatric population health, emphasizing personalised medicines and proactive management of lifestyle disorders. Insurance companies often collaborate to ensure comprehensive coverage and access to necessary treatments.

Request PDF sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch